MetaCap

Teva Pharmaceutical Industries Limited (TEVA)

NYSE: TEVAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

39.23+0.69 (+1.79%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TEVA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$45.77B
Ex-dividend date
Nov 27, 2017
52-week range
24.34 – 44.57
Day range
38.30 – 39.91
Volume / Avg
6.81M / 6.31M
Beta
—

52-week range

$24.34$44.57

TEVA stock today

On Nov 20, TEVA ended the session at $39.23, adding $0.69 (1.79%), versus the S&P 500's 3.70% decline. At this level, TEVA sits in the middle of its 52-week range of $24.34 to $44.57: 12.0% below the high, set on Nov 13, 2026 and 61.2% above the low. TEVA is up 25.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 62.0%.

At 91.2x trailing earnings, Teva Pharmaceutical Industries trades above the peer-group median of 43.2x. Its forward P/E of 12.5x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Teva Pharmaceutical Industries

Company profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Richard D. Francis
Headquarters
Tel Aviv-Yafo
Employees
31,173

Financial highlights

Full financials

In fiscal 2025, Teva Pharmaceutical Industries generated $17.26 billion in revenue, up 4.3% from fiscal 2024, its 3rd consecutive year of revenue growth. Net income was $1.41 billion, for a net margin of 8.2% versus a median of -9.9% in the prior 5 years. Gross margin was 51.8% (up from 48.7%) and operating margin 12.5%.

Teva Pharmaceutical Industries annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$17.26B$16.54B$15.85B$14.93B$15.88B
Growth+4.32%+4.40%+6.17%-6.00%-4.69%
Net income$1.41B$-1.64B$-559.00M$-2.45B$417.00M
EPS (diluted)$1.21$-1.45$-0.50$-2.20$0.38

Analyst forecast

Forecast

Consensus (15 analysts)

buy

Avg. price target

$50.29+28.19%

  • Strong buy 4
  • Buy 9
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $42.12High $57.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$0.20 vs $0.70
Surprise
-71.43%

Dividends

Dividend history
Annual dividend
$0.00
Last payment
$0.085
Ex-dividend date
Nov 27, 2017

TEVA news

All TEVA news

Teva Pharmaceutical Industries peers

Health Care sector
TEVA peer companies
CompanyPrice% ChgMarket capCompare
ONCBeOne Medicines Ltd. ADR390.94-2.19%$44.66Bvs TEVA
RPRXRoyalty Pharma plc Class A68.45+1.08%$39.36Bvs TEVA
ZTSZoetis Inc. Class A79.11-2.08%$32.14Bvs TEVA
GMABGenmab A/S ADS50.60-1.46%$31.20Bvs TEVA
INSMInsmed Incorporated141.33-2.17%$31.01Bvs TEVA
ROIVRoivant Sciences Ltd.38.66-0.78%$28.01Bvs TEVA
UTHRUnited Therapeutics Corporation554.73-0.78%$23.63Bvs TEVA
VTRSViatris Inc.19.63-1.26%$22.50Bvs TEVA

Indexes, lists and sector

Teva Pharmaceutical Industries stock FAQ

What is Teva Pharmaceutical Industries's stock price today?

TEVA last traded at $39.23 as of Nov 20, 4:00 PM EST, up 1.79% on the day. Prices are delayed at least 15 minutes.

Does Teva Pharmaceutical Industries pay a dividend?

Yes. Teva Pharmaceutical Industries pays $0.00 per share annually. The most recent dividend of $0.085 had an ex-dividend date of Nov 27, 2017.

What is TEVA's P/E ratio?

TEVA trades at a trailing P/E ratio of 91.23 and a forward P/E of 12.53, compared with a median of 43.2 for its closest peers.

Who is Teva Pharmaceutical Industries's CEO?

Mr. Richard D. Francis is the chief executive officer of Teva Pharmaceutical Industries Limited, which has about 31,173 employees.

Has TEVA ever split its stock?

Yes. The most recent TEVA stock split was a 2-for-1 split on Jul 1, 2004, one of 4 splits on record.

What is the TEVA 52-week high?

The 52-week high for TEVA is $44.57 and the 52-week low is $24.34. The stock is currently 12.0% below its high.

Compare TEVA